is this talking about colloidal silver?
brenda b
-----OriginalCANCERLIT® Citation
AUTHOR:
Hochster H, Liebes L, Speyer J, Sorich J,
Chachoua A, Raphael B, Moskovits T,
Taubes B, Friedberg A, Buckley M, Fry D, Arbuck
S, Blum R, Potmesil M
TITLE:
Phase I and pharmacodynamic study of prolonged
infusion 9-amino-camptothecin
(9AC) in two formulations (Meeting abstract).
SOURCE:
Proc Annu Meet Am Soc Clin Oncol; 16:A704 1997
UI: 98642704
LINKS:
Clinical trials that cite this article
ABSTRACT:
Based on colon xenograft studies suggesting
improved therapeutic index for 9-AC
prolonged administration, and the 72-hr infusion
MTD, we began this study of 9-AC
at a dose of 6.2 ug/m2/hr x 7 days q 28 days with
the DMA/PEG formulation.
Infusion duration and dose was escalated as
below. For the CD (colloidal dispersion)
formulation dosing began at 14.1 ug/m2/hr. 42 pts
with adequate organ function were
entered: 10 male and 32 female (DMA 33 and CD 9
pts), 41 prior chemotherapy
(med 3 regimens), 10 prior RT, median age 61
years (range 40-82). Diagnoses
included: ovarian 17 pts, colorectal 12, breast
3, unk primary 2, cholangio 2 and 1
each lung, pancreas, renal, cervix, MF, NHL. 131
cycles were given. In the DMA
cohorts no toxicity was seen at 6.2 x 7, 10, 14,
17 or 21 days or 9.4 x 21 days.
Further heme toxicities are shown in a table.
Non-heme tox included: alopecia gr 1 (9
pts), gr 2 (4) [all greater than or equal to
18.75]; N/V gr 2 (3), gr 3 (3); fatigue gr 1
(8), gr 2(2); neuropathy gr 1 (2). PR was seen in
ovarian (2 pts) and breast ca; SD in
6 ovarian, 4 colon, and 2 unk primary. Css for
total 9-AC in DMA ranged from 1.28
ng/ml to 6.48 (n=36, r2=0.88); 6/8 pts showed
more than 50% depletion of topo-1
in PBMCs, including some at 6.2 level; additional
data to be presented including
comparison of DMA vs CD. MTD for DMA is 18.75
ug/m2/hr (0.4 mg/m2/day)
and will likely be 21.1 - 25 for CD formulation.
Accrual continues for CD at 25 ug x
21 days. (C) American Society of Clinical
Oncology 1997
LANGUAGE:
ENG
PUBLICATION TYPE:
MEETING ABSTRACTS
CLINICAL TRIAL
CLINICAL TRIAL, PHASE I
TITLE ABBREVIATION:
Proc Annu Meet Am Soc Clin Oncol
YEAR:
1997
ADDRESS:
Kaplan Cancer Ctr, NYU Med Ctr, NY, NY 10016
ENTRY MONTH:
199802
CAS NO.:
86639-63-6 (9-amino-20-camptothecin)
0 (Antineoplastic Agents, Combined)
7689-03-4 (Camptothecin)
0 (Dosage Forms)
home help dictionary search
